A tüdorák felismerésének, diagnosztiká jának és kezelésének korszeru elvei

Translated title of the contribution: Modern principles of early detection, diagnosis and treatment in lung cancer

G. Ostoros, Gábor Kovács, Nagy György Böszörményi, J. Strausz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

New clinical guidelines for the diagnosis and treatment of lung cancer contain important advancements. It is necessary therefore that these novelties are widely known by health care professionals. With an existing X-ray screening network in Hungary, we have a unique chance to discover lung malignancies in an early stage in the population. Annual screening is recommended in risk groups over 40 years of age using a nation wide established digital screening network technology. In the therapy of small cell lung cancer there has been no major advance in the past ten years. However, by today, the number of small cell lung cancer patients represent only about 15% of all lung cancer cases. There have been advancements in other fields of the therapy of non small cell lung cancer. Third generation cytotoxic agents used in a platinum based chemotherapy protocol improved quality of life, response rate and survival time. Radiochemotherapy used in locally advanced stages also represented a step forward. In early stage of non small cell lung cancer it has been revealed that significantly improved survival time can be reached with adjuvant combined cytotoxic chemotherapy. Based on these results adjuvant chemotherapy became part of the therapeutic protocol. The use of molecular targeted chemotherapy in the clinical practice of non small cell lung cancer treatment is also a novelty. New therapeutic approaches are epidermal growth factor inhibitors, angiogenesis inhibitors, antivascular, signal transduction modifiers, apoptosis inducing, eicosanoid signal transduction modifiers and immunotherapeutic drugs. Placebo controlled trials have proved the effectiveness of the epidermal growth factor tyrosine kinase inhibitor erlotinib in the second and third line therapy of non small cell lung cancer and can he administered in the European Union in this indication. The improvement in the complex care of lung cancer patients in Hungary is characterized by the gradual increase in the prevalence data, meaning the gradual increase of the number of lung cancer patients still alive.

Original languageHungarian
Pages (from-to)11-16
Number of pages6
JournalLege Artis Medicinae
Volume16
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

Early Diagnosis
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Hungary
Small Cell Lung Carcinoma
Epidermal Growth Factor
Drug Therapy
Therapeutics
Signal Transduction
Angiogenesis Inhibitors
Eicosanoids
Cytotoxins
Chemoradiotherapy
European Union
Adjuvant Chemotherapy
Platinum
Protein-Tyrosine Kinases
Survival Rate
Placebos
Quality of Life

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A tüdorák felismerésének, diagnosztiká jának és kezelésének korszeru elvei. / Ostoros, G.; Kovács, Gábor; Böszörményi, Nagy György; Strausz, J.

In: Lege Artis Medicinae, Vol. 16, No. 1, 01.2006, p. 11-16.

Research output: Contribution to journalArticle

Ostoros, G. ; Kovács, Gábor ; Böszörményi, Nagy György ; Strausz, J. / A tüdorák felismerésének, diagnosztiká jának és kezelésének korszeru elvei. In: Lege Artis Medicinae. 2006 ; Vol. 16, No. 1. pp. 11-16.
@article{11106f798c1c4ff3bc9f1e78b0f12ae1,
title = "A t{\"u}dor{\'a}k felismer{\'e}s{\'e}nek, diagnosztik{\'a} j{\'a}nak {\'e}s kezel{\'e}s{\'e}nek korszeru elvei",
abstract = "New clinical guidelines for the diagnosis and treatment of lung cancer contain important advancements. It is necessary therefore that these novelties are widely known by health care professionals. With an existing X-ray screening network in Hungary, we have a unique chance to discover lung malignancies in an early stage in the population. Annual screening is recommended in risk groups over 40 years of age using a nation wide established digital screening network technology. In the therapy of small cell lung cancer there has been no major advance in the past ten years. However, by today, the number of small cell lung cancer patients represent only about 15{\%} of all lung cancer cases. There have been advancements in other fields of the therapy of non small cell lung cancer. Third generation cytotoxic agents used in a platinum based chemotherapy protocol improved quality of life, response rate and survival time. Radiochemotherapy used in locally advanced stages also represented a step forward. In early stage of non small cell lung cancer it has been revealed that significantly improved survival time can be reached with adjuvant combined cytotoxic chemotherapy. Based on these results adjuvant chemotherapy became part of the therapeutic protocol. The use of molecular targeted chemotherapy in the clinical practice of non small cell lung cancer treatment is also a novelty. New therapeutic approaches are epidermal growth factor inhibitors, angiogenesis inhibitors, antivascular, signal transduction modifiers, apoptosis inducing, eicosanoid signal transduction modifiers and immunotherapeutic drugs. Placebo controlled trials have proved the effectiveness of the epidermal growth factor tyrosine kinase inhibitor erlotinib in the second and third line therapy of non small cell lung cancer and can he administered in the European Union in this indication. The improvement in the complex care of lung cancer patients in Hungary is characterized by the gradual increase in the prevalence data, meaning the gradual increase of the number of lung cancer patients still alive.",
keywords = "Early detection, Lung cancer, Molecular target therapy, Multimodality treatment",
author = "G. Ostoros and G{\'a}bor Kov{\'a}cs and B{\"o}sz{\"o}rm{\'e}nyi, {Nagy Gy{\"o}rgy} and J. Strausz",
year = "2006",
month = "1",
language = "Hungarian",
volume = "16",
pages = "11--16",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "1",

}

TY - JOUR

T1 - A tüdorák felismerésének, diagnosztiká jának és kezelésének korszeru elvei

AU - Ostoros, G.

AU - Kovács, Gábor

AU - Böszörményi, Nagy György

AU - Strausz, J.

PY - 2006/1

Y1 - 2006/1

N2 - New clinical guidelines for the diagnosis and treatment of lung cancer contain important advancements. It is necessary therefore that these novelties are widely known by health care professionals. With an existing X-ray screening network in Hungary, we have a unique chance to discover lung malignancies in an early stage in the population. Annual screening is recommended in risk groups over 40 years of age using a nation wide established digital screening network technology. In the therapy of small cell lung cancer there has been no major advance in the past ten years. However, by today, the number of small cell lung cancer patients represent only about 15% of all lung cancer cases. There have been advancements in other fields of the therapy of non small cell lung cancer. Third generation cytotoxic agents used in a platinum based chemotherapy protocol improved quality of life, response rate and survival time. Radiochemotherapy used in locally advanced stages also represented a step forward. In early stage of non small cell lung cancer it has been revealed that significantly improved survival time can be reached with adjuvant combined cytotoxic chemotherapy. Based on these results adjuvant chemotherapy became part of the therapeutic protocol. The use of molecular targeted chemotherapy in the clinical practice of non small cell lung cancer treatment is also a novelty. New therapeutic approaches are epidermal growth factor inhibitors, angiogenesis inhibitors, antivascular, signal transduction modifiers, apoptosis inducing, eicosanoid signal transduction modifiers and immunotherapeutic drugs. Placebo controlled trials have proved the effectiveness of the epidermal growth factor tyrosine kinase inhibitor erlotinib in the second and third line therapy of non small cell lung cancer and can he administered in the European Union in this indication. The improvement in the complex care of lung cancer patients in Hungary is characterized by the gradual increase in the prevalence data, meaning the gradual increase of the number of lung cancer patients still alive.

AB - New clinical guidelines for the diagnosis and treatment of lung cancer contain important advancements. It is necessary therefore that these novelties are widely known by health care professionals. With an existing X-ray screening network in Hungary, we have a unique chance to discover lung malignancies in an early stage in the population. Annual screening is recommended in risk groups over 40 years of age using a nation wide established digital screening network technology. In the therapy of small cell lung cancer there has been no major advance in the past ten years. However, by today, the number of small cell lung cancer patients represent only about 15% of all lung cancer cases. There have been advancements in other fields of the therapy of non small cell lung cancer. Third generation cytotoxic agents used in a platinum based chemotherapy protocol improved quality of life, response rate and survival time. Radiochemotherapy used in locally advanced stages also represented a step forward. In early stage of non small cell lung cancer it has been revealed that significantly improved survival time can be reached with adjuvant combined cytotoxic chemotherapy. Based on these results adjuvant chemotherapy became part of the therapeutic protocol. The use of molecular targeted chemotherapy in the clinical practice of non small cell lung cancer treatment is also a novelty. New therapeutic approaches are epidermal growth factor inhibitors, angiogenesis inhibitors, antivascular, signal transduction modifiers, apoptosis inducing, eicosanoid signal transduction modifiers and immunotherapeutic drugs. Placebo controlled trials have proved the effectiveness of the epidermal growth factor tyrosine kinase inhibitor erlotinib in the second and third line therapy of non small cell lung cancer and can he administered in the European Union in this indication. The improvement in the complex care of lung cancer patients in Hungary is characterized by the gradual increase in the prevalence data, meaning the gradual increase of the number of lung cancer patients still alive.

KW - Early detection

KW - Lung cancer

KW - Molecular target therapy

KW - Multimodality treatment

UR - http://www.scopus.com/inward/record.url?scp=32044432798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044432798&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 11

EP - 16

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 1

ER -